A retrospective trial of ruxolitinib as salvage-therapy for graft-versus-host disease (GVHD)

Trial Profile

A retrospective trial of ruxolitinib as salvage-therapy for graft-versus-host disease (GVHD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results of long-term follow-up, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 22 Jan 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top